BTK and acute myeloid leukemia: This suggested the role of BTK as a potential therapeutic target in acute myeloid leukemia, so preclinical and clinical studies are performed to estimate the BTK selective inhibitor ibrutinib usage in the treatment of AML [33,36,37,38].